Therapeutic formulation and methods of treatment

An ophthalmic composition, consisting essentially of:

• a pharmaceutically active drug comprising hydralazine in an amount between about 0.02-2 wt %;
• an acetate buffer solution having pH of between 3.9-4.5 in an amount between 8-12 wt %;
• propylene glycol in an amount between 0.5-2 wt %;
• sodium chloride in an amount between 0.25-1 wt %;
• methylparaben in an amount between 0.015-0.06 wt %;
• benzalkonium chloride in the form of a 50% solution, present in an amount between 0.01-0.04 wt %;
• and
• edetate disodium in an amount between 0.008-0.030 wt %;
• wherein said composition has a pH of between 4.0-4.4;
• wherein a decrease in the w/w % of the active drug is less than about 10% after one month storage.